Table 1. Characteristics of Swedish patients who underwent HSCT between 2006 and 2015 and survived ≥6 months post-HSCT by cGVHD status.
| Non-cGVHD | Mild cGVHD | Moderate-Severe cGVHD | P value* | Overall | |
|---|---|---|---|---|---|
| Total (%) | 350 (28) | 345 (28) | 551 (44) | 1246 (100) | |
| Sex, No. (%) | 0.618 | ||||
| Men | 206 (59) | 192 (56) | 323 (59) | 721 (58) | |
| Women | 144 (41) | 153 (44) | 228 (41) | 525 (42) | |
| Age at HSCT, No. (%) | 0.623 | ||||
| 18 to 39 years of age | 92 (26) | 79 (23) | 132 (24) | 303 (24) | |
| 40 to 59 years of age | 147 (42) | 164 (48) | 256 (46) | 567 (46) | |
| 60 to 75 years of age | 111 (32) | 102 (30) | 163 (30) | 376 (30) | |
| Median age, years (Q1-Q3) | 53 (41–61) | 52 (40–61) | 52 (39–62) | 0.985 | 52 (40–61) |
| Year of HSCT, No. (%) | 0.758 | ||||
| 2006 to 2010 | 116 (33) | 122 (35) | 195 (35) | 433 (35) | |
| 2011 to 2015 | 234 (67) | 223 (65) | 356 (65) | 813 (65) | |
| Diagnosis before HSCT, No. (%) | 0.002 | ||||
| Acute leukemia | 222 (63) | 178 (52) | 281 (51) | 681 (55) | |
| Lymphoma | 31 (9) | 54 (16) | 64 (12) | 149 (12) | |
| Myelodysplastic syndrome | 34 (10) | 40 (12) | 72 (13) | 146 (12) | |
| Chronic leukemia | 27 (8) | 45 (13) | 75 (14) | 147 (12) | |
| Other hematologic malignancy | 36 (10) | 28 (8) | 59 (11) | 123 (10) | |
| Donor, No. (%) | <0.0001 | ||||
| Related | 95 (27) | 88 (26) | 209 (38) | 392 (31) | |
| Unrelated | 255 (73) | 257 (74) | 342 (62) | 854 (69) | |
| Source for HSCT, No. (%) | 0.312 | ||||
| Bone marrow/cord blood | 76 (22) | 91 (26) | 126 (23) | 293 (24) | |
| PBSC | 274 (78) | 254 (74) | 425 (77) | 953 (76) |
PBSC indicates peripheral blood stem cells; Q, quartile.
*P value for the univariate (Chi-square and Kruskal-Wallis) test of hypothesis of no difference between the three cGVHD groups.